PhaseBio Pharmaceuticals (NASDAQ:PHAS) is a clinical-stage biopharmaceutical company developing novel drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. Initial focus is for cardiopulmonary indications. The effort is to leverage the firm's proprietary elastin-like polypeptide technology to advance a pipeline of drug candidates with the potential for less frequent dosing and better patient compliance.The firm's lead program PB2452 is a reversal agent for the antiplatelet drug ticagrelor (Brilinta). The Phase I candidate was in-licensed from MedImmune in 2017 and is in development for patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. PhaseBios other clinical-stage program PB1046 is a once-weekly fusion protein in Phase IIb for pulmonary arterial hypertension. The compound incorporates the firms elastin-like polypeptide (ELP) technology, which extends the circulating half-life of proteins and peptides, provides a sustained-release mechanism, and enhances solubility, stability and bioavailability of the active ingredient.
